The earnings call reflects a company focused on significant upcoming product launches and managing existing portfolio challenges. While the performance of the ADHD portfolio and progress towards the EXXUA launch highlight growth and strategic focus, declines in certain segments and regulatory concerns pose challenges.
Company Guidance
During the Aytu BioPharma Fiscal 2026 Q1 earnings call, the company reported net revenue of $13.9 million, with their ADHD portfolio showing a 10% increase in net revenue compared to the previous year, when excluding a one-time rebate benefit. The EXXUA launch is on track for the end of calendar year 2025, with significant advancements in product manufacturing, sales force training, and marketing strategies. The company is maintaining a sales force of approximately 40 people and aligning territories to optimize patient access. Aytu anticipates a $50 million operational expenditure for fiscal 2026, inclusive of a $10 million EXXUA launch investment. Cash and cash equivalents stood at $32.6 million as of September 30, 2025. The company projects that achieving quarterly net revenue of $17.3 million will bring them to breakeven, emphasizing their confidence in the potential of EXXUA as a transformative product for treating major depressive disorder.
Positive Revenue Performance in ADHD Portfolio
Net revenue for the ADHD portfolio increased by approximately 10% year-over-year when excluding a one-time rebate benefit from the previous year, showcasing strong performance against expectations.
EXXUA Launch Progress
The EXXUA launch remains on track for the end of calendar 2025 with significant advancements in KOL engagement, sales force training, and product positioning.
Patent Extension for EXXUA
Successfully extended the EXXUA method of use patent to September 2030, enhancing intellectual property protection.
Strong Cash Position
Cash and cash equivalents were $32.6 million at the end of the quarter, up from $31 million in the previous quarter.
Aytu BioScience (AYTU) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AYTU Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$2.06
$2.09
+1.46%
Sep 23, 2025
$2.51
$2.06
-17.93%
May 14, 2025
$1.35
$2.59
+91.85%
Feb 12, 2025
$1.39
$1.38
-0.72%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on Feb 18, 2026, TBA (Confirmed).
What is Aytu BioScience Inc (AYTU) earnings time?
Aytu BioScience Inc (AYTU) earnings time is at Feb 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.